Page last updated: 2024-12-05

furazolidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3435
CHEMBL ID1374738
CHEBI ID5195
SCHEMBL ID64995
MeSH IDM0008899
PubMed CID5323714
CHEMBL ID1103
SCHEMBL ID64996
MeSH IDM0008899

Synonyms (221)

Synonym
furoxone
KBIO1_000085
DIVK1C_000085
SPECTRUM_001098
furazolidona [inn-spanish]
furox aerosol powder (veterinary)
hsdb 7036
nsc 6469
einecs 200-653-3
furazolum
furazolidonum [inn-latin]
ai3-50103
nifurazolidonum
ccris 1540
nf 180 custom mix ten
PRESTWICK_1067
OPREA1_494195
furazolidone
67-45-8
KBIO3_001272
KBIO2_006714
KBIOGR_001257
KBIO2_001578
KBIOSS_001578
KBIO2_004146
PRESTWICK0_000808
SPBIO_002596
SPECTRUM2_001015
SPECTRUM3_000436
PRESTWICK1_000808
NINDS_000085
SPECTRUM4_000559
SPBIO_001169
CHEBI:5195 ,
furazolidona
furazolidonum
HMS1570B17
3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
HMS2097B17
F0821
dtxsid4041997 ,
HMS2233B03
unii-5j9cpu3re0
5j9cpu3re0 ,
furazolidone [usp:inn:ban]
FT-0601637
AKOS016339589
HMS3370L21
CCG-220808
SCHEMBL64995
KS-5321
CHEMBL1374738
AKOS025392178
3-(5-nitro-furfuryliden-amino)-oxazolidin-2-on
HMS3714B17
gtpl12343
BIDD:GT0182
CHEMBL1103
BRD-K11756522-001-03-2
BRD-K10647544-001-02-0
trichofuron
nifulidone
wln: t5oj bnw e1un- at5nvotj
coryzium
optazol
puradin
3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
giarlam
diafuron
giardil
nitrofurazolidone
component of topazone
furazol
nsc6469
nicolen
usaf ea-1
tricofuron
furidon
ortazol
furoxane
n-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone
nitrofuroxon
3-[(5-nitrofurfurylidene)amino]-2-oxazolidone
trifurox
furazolidine
nf 180
furoxal
furoxone swine mix
2-oxazolidinone, 3-[(5-nitrofurfurylidene)amino]-
3-(5'-nitrofurfuralamino)-2-oxazolidone
furazon
furall
medaron
furaxone
furoxon
nsc-6469
3-[(5-nitrofurylidene)amino]-2-oxazolidone
furozolidine
furaxon
roptazol
tikofuran
2-oxazolidinone, 3-[(5-nitrofurfurylidine)amino]-
2-oxazolidinone, 3-[[(5-nitro-2-furanyl)methylene]amino]-
component of tricofuron
furazolidon
topazone
2-furanmethanimine, 5-nitro-n-(2-oxo-3-oxazolidinyl)-
neftin
tricoron
smr000058228
MLS000069727 ,
BSPBIO_002052
PRESTWICK3_000808
viofuragyn
2-oxazolidinone, 3-((5-nitrofurfurylidine)amino)-
bifuron
nifurazolidone
2-oxazolidinone, 3-(((5-nitro-2-furanyl)methylene)amino)-
furox
3-(((5-nitro-2-furanyl)methylene)amino)-2-oxazolidinone
furovag
nifuran
2-oxazolidinone, 3-((5-nitrofurfurylidene)amino)-
enterotoxon
3-((5-nitrofurfurylidene)amino)-2-oxazolidinone
3-((5-nitrofurylidene)amino)-2-oxazolidone
corizium
nitrofurazolidonum
3-((5-nitrofurfurylidene)amino)-2-oxazolidone
sclaventerol
cas-67-45-8
PRESTWICK2_000808
BPBIO1_000743
BSPBIO_000675
3-[(e)-(5-nitro-2-furyl)methyleneamino]oxazolidin-2-one
3-[[(5-nitro-2-furanyl)methylene]amino]-2-oxazolidinone
IDI1_000085
SPECTRUM5_000742
AB00443658
C07999
inchi=1/c8h7n3o5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5h,3-4h2/b9-5
3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
5-nitro-n-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
n-(5-nitro-2-furfurylidene)-3-aminooxazolidine-2-one
DB00614
fzl ,
NCGC00095304-02
D00830
furoxone (tn)
furazolidone (usp/inn)
NCGC00095304-01
SPECTRUM1500309
NCGC00095304-04
MLS001304180
NCGC00095304-03
F-8900 ,
furazolidone, antibiotic for culture media use only
STK388219
3-{[(e)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
HMS2091H03
AC-11695
3-[[(5-nitro-2-furanyl)methylene]-amino]-2-oxazolidinone
HMS500E07
3-[(e)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
HMS1920O22
AKOS001678302
3-[(e)-(5-nitro-2-furanyl)methylideneamino]-2-oxazolidinone
A835757
NCGC00188974-01
dtxcid60809632
tox21_111502
pharmakon1600-01500309
nsc-757038
nsc757038
S4528
CCG-40233
fiurox aerosol powder
furazolidone [orange book]
furazolidone [iarc]
furazolidone [who-dd]
furazolidone [hsdb]
furazolidone [green book]
furazolidone [usp monograph]
furazolidone [inn]
furazolidone [usp impurity]
furazolidone [mart.]
furazolidone [usp-rs]
furazolidone [mi]
SCHEMBL64996
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
NCGC00095304-05
tox21_111502_1
CS-4897
3-([(5-nitro-2-furyl)methylidene]amino)-1,3-oxazolidin-2-one #
PLHJDBGFXBMTGZ-WEVVVXLNSA-N
AC-32486
HY-B1336
AB00052000_03
OPERA_ID_256
mfcd00010550
SR-05000001632-1
sr-05000001632
furazolidone, vetranal(tm), analytical standard
furazolidone, united states pharmacopeia (usp) reference standard
SR-05000001632-3
EN300-122609
furazolidone, vetec(tm) reagent grade
Z57152562
SBI-0051388.P003
3-[(5-nitrofurfurylidine)amino]-2-oxazolidinone
3-((5-nitrofurfurylidine)amino)-2-oxazolidinone
3-[[(5-nitro-2-furanyl)methylene]amino]-2-oxazolidinone, 9ci
A16011
3-(((5-nitrofuran-2-yl)methylene)amino)oxazolidin-2-one
BRD-K11756522-001-04-0
CCG-266758
NCGC00095304-06
EN300-21037330
3-[(e)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolan-2-one

Research Excerpts

Overview

Furazolidone (FZD) is a widely used drug in human and veterinary medicine, and has antibacterial and antiprotozoal action. It is a much cheaper drug with a very low resistance against Helicobacter pylori compared to clarithromycin. Furazolid one is a bactericidal agent used to treat infectious ente.

ExcerptReferenceRelevance
"Furazolidone (FZD) is a widely used drug in human and veterinary medicine, and has antibacterial and antiprotozoal action. "( What are the immunopharmacological effects of furazolidone? A systematic review.
Costa, AG; Feitosa, IB; Mori, B; Santos, APAD; Teles, CBG; Villanova, JCO, 2021
)
2.32
"Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial action and has been widely used in the treatment of Helicobacter pylori (H. "( Risk factors of furazolidone-associated fever.
Chen, J; Dai, H; Rong, C; Yan, C; Yang, W; Yu, L; Zhang, J, 2022
)
2.51
"Furazolidone is a nitrofuran antimicrobial agent used in the treatment of bacterial and protozoal infections. "( Delayed-type allergic reaction to furazolidone: A case report and review of the literature.
Meng, J; Xiao, H; Xu, F; Zhang, H, 2023
)
2.63
"Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity and is used for the treatment of giardiasis."( Furazolidone is a selective in vitro candidate against Leishmania (L.) chagasi: an ultrastructural study.
Reimão, JQ; Taniwaki, NN; Tempone, AG, 2010
)
2.52
"Furazolidone is a much cheaper drug with a very low resistance against Helicobacter pylori compared to clarithromycin. "( Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010
)
2.11
"Furazolidone (FZD) is an antimicrobial agent that has been shown to have mutagenic, genotoxic and potentially carcinogenic properties when tested in a variety of systems in vitro and in vivo. "( Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells.
Chen, Q; Jin, X; Liu, F; Sun, C; Tang, S; Xiao, X; Zhang, S; Zhang, T; Zou, J, 2011
)
3.25
"Furazolidone is a very good substitute for metronidazole and clarithromycin, but its many side-effects limit widespread use."( Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori.
Butorab, Z; Massarrat, S; Roghani, HS; Shirekhoda, M, 2003
)
1.33
"Furazolidone is a bactericidal agent used to treat infectious enteropathies. "( Furazolidone-induced pulmonary hypersensitivity.
Henry, MJ; Kowalski, TJ; Zlabek, JA, 2005
)
3.21
"Furazolidone (FUZ) is a nitrofuran drug, which has been used for many years as an antibacterial drug in veterinary practice."( Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats.
Abdel-Wahhab, MA; Ahmed, HH; El-Aziem, SH, 2008
)
1.28
"Furazolidone agar proved to be a suitable medium for separating strains of the genera Micrococcus and Staphylococcus. "( Rapid distinction between micrococci and staphylococci with furazolidone agars.
Hadlok, RM; von Rheinbaben, KE, 1981
)
1.95
"Furazolidone is a nitrofuran antibiotic that causes dilated cardiomyopathy in turkeys and chicks and serves as an important model of human dilated cardiomyopathy. "( Furazolidone increases thapsigargin-sensitive Ca(2+)-ATPase in chick cardiac myocytes.
Gillies, RJ; Lax, D; Martínez-Zaguilán, R, 1994
)
3.17
"Furazolidone appears to be a satisfactory alternative to chloramphenicol in the treatment of typhoid fever caused by chloramphenicol-resistant strains of S."( Randomized clinical trial of furazolidone for typhoid fever in children.
Chakraborty, S; Dutta, P; Manna, B; Mitra, U; Mukherjee, A; Rasaily, R; Saha, MR, 1993
)
1.3
"Furazolidone is an antimicrobial compound used in human and veterinary medicine. "( Effect of furazolidone on sister-chromatid exchanges, cell proliferation kinetics, and mitotic index in vivo and in vitro.
Cassani, M; Chamorro, G; Ibañez, JC; Madrigal-Bujaidar, E, 1997
)
2.14
"Furazolidone is an inexpensive antibiotic that has considerable anti-Helicobacter pylori activity in vitro."( Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week.
Kooy, A; Thijs, JC; van der Wouden, EJ; Van Zwet, AA, 1997
)
1.98
"Furazolidone (FZ) is a nitrofuran drug commonly used in aquaculture. "( Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout.
Grudzinski, IP; Law, FC; Mangat, SS; Meng, J, 1998
)
2.09
"Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days."( Treatment of giardiasis.
Gardner, TB; Hill, DR, 2001
)
1.03
"Furazolidone is a nitrofuran drug which causes dilated cardiomyopathy in turkeys and serves as an important model of human dilated cardiomyopathy. "( Generation of furazolidone radical anion and its inhibition by glutathione.
Kukolich, SG; Lax, D, 1992
)
2.09
"Furazolidone is an example of an effective veterinary drug, the use of which should be limited by the fact that detoxification mechanisms of the animals, may result in the appearance of reactive metabolites which are available in the gastro-intestinal tract of the consumer."( [Toxicological considerations in the evaluation of veterinary drugs].
Jager, LP; Vroomen, LH, 1990
)
1
"Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial action and has been widely used in the treatment of gastrointestinal infections. "( Adverse reactions to furazolidone and other drugs. A comparative review.
Altamirano, A; Bondani, A, 1989
)
2.04
"Furazolidone is a single, broad-spectrum antimicrobial that is effective, relatively safe, specific, and is orally administered in tablet or suspension form."( Furazolidone for treatment of diarrhoeal disease.
Hailey, FJ; Phillips, KF, 1987
)
2.34

Effects

Furazolidone has been effective against Helicobacter pylori in Iran, with no resistance, but with intolerable side effects in the second week. It has been banned from use in food animals because of its carcinogenicity and mutagenicity, but its continued misuse is widespread in aquacultures.

ExcerptReferenceRelevance
"Furazolidone has been used in the treatment of certain bacterial and protozoan infections in human and animals for more than sixty years."( A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia.
Dong, S; Jiang, X; Li, S; Qiu, JJ; So, CW; Sun, L; Sun, X; Wang, X, 2013
)
1.42
"Furazolidone has proven to have antiprotozoal and antibacterial activity. "( Formulation and advantages of furazolidone in liposomal drug delivery systems.
Alam, MI; Elkordy, AA; Paget, T, 2016
)
2.17
"Furazolidone has been banned from use in food animals because of its carcinogenicity and mutagenicity, but its continued misuse is widespread in aquacultures. "( Application of a modified enzyme-linked immunosorbent assay for 3-amino-2-oxazolidinone residue in aquatic animals.
Chang, C; Huang, L; Ihsan, A; Liu, Y; Peng, D; Tao, Y; Wang, Y; Yang, B; Yuan, Z, 2010
)
1.8
"Furazolidone has been introduced as an effective drug against Helicobacter pylori infection in Iran, but intolerable side effects may limit its use. "( Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011
)
3.25
"Furazolidone has recently shown promising efficacy in H. "( The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.
Bahrami, H; Ebrahimi-Dariani, N; Haghpanah, B; Mansour-Ghanaei, F; Mirmomen, S; Noormohammadpoor, P; Sotodehmanesh, R, 2003
)
2.11
"Furazolidone has been effective against Helicobacter pylori in Iran, with no resistance, but with intolerable side effects in the second week. "( Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease.
Agah, S; Ajvadi, Y; Ali-Asgari, A; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Nasseri-Moghaddam, S; Pourshams, A; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2007
)
3.23
"Furazolidone (FZ) has been used in China as a treatment of peptic ulcer disease for about 20 years. "( Treatment of peptic ulcer disease with furazolidone.
Wang, YB; Zheng, ZT,
)
1.84
"Furazolidone has normally been administered as a non-absorbable antimicrobial agent for use in gastrointestinal infections. "( Detection of furazolidone in human biological fluids by high performance liquid chromatography.
Guiscafre-Gallardo, H; Muñoz, O; Sanchez-Garcia, S; Valadez-Salazar, A, 1989
)
2.09
"Furazolidone (Furoxone) has been used for 30 years for the specific and symptomatic treatment of bacterial or protozoal diarrhoea and enteritis caused by susceptible organisms."( The use of furoxone: a perspective.
Hailey, FJ; Phillips, KF, 1986
)
0.99

Treatment

Furazolidone-containing treatments could achieve satisfactory eradication rates. The incidence of milder side effects, such as fever and anorexia, should be considered when prescribing the treatments.

ExcerptReferenceRelevance
"Furazolidone-containing treatments could achieve satisfactory eradication rates and did not increase the incidence of total or severe adverse effects, but the incidence of milder side effects, such as fever and anorexia, should be considered when prescribing furazolidone-containing treatments to patients."( Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis.
Li, Z; Wang, Y; Wu, S; Xie, Y; Zhao, RL; Zhuge, L, 2018
)
2.64
"In furazolidone-treated birds with resultant cardiac dilation there was myocyte hypertrophy, enlargement of nuclei and reorientation of subepicardial myocardial fibres."( Morphological changes associated with furazolidone-induced cardiomyopathy: effects of digoxin and propranolol.
Gwathmey, JK, 1991
)
1.07
"Furazolidone treatment caused significant reduction in semen volume as well as sperm concentration in either genotype."( Effect of orally administered furazolidone on volume and sperm concentration of dwarf and non-dwarf cock semen.
Datta, IC; Gehlaut, BS; Mangle, NS, 1989
)
1.29
"The treatment used furazolidone + β-cyclodextrin complex (1: 2) at a concentration of 60 mg/mL given orally at a dose of 15 mg/kg every 12 hours."( Treatment of canine cutaneous leishmaniasis by Leishmania (Viannia) braziliensis in dogs with furazolidone and β-cyclodextrin: case report.
Ataíde Siqueira, L; Gnecco Zanini, D; Madureira, AP; Ramos Sobreira, R; Santos Zanini, M; Savergnini Poleze, L; Vieira Almeida, Y, 2022
)
1.26
"Treatment with furazolidone contributed to the development of lactase deficit and delayed stools normalization."( [Clinico-pathogenetic basis for using crystalline lysozyme in the combined therapy of food toxinfections].
Andreĭchin, MA; Ishchuk, IS; Kitaĭ, GP,
)
0.47
"Treatment with furazolidone for seven days resulted in substantial retardation of growth."( [Effects of growth-stimulating agents and furazolidone in broiler chicks].
Stappers, HP; Vahl, HA, 1985
)
0.87

Toxicity

Furazolidone-containing quadruple regimens proved both safe and highly effective in a real-world setting. The cytotoxicity of nitrofuran drugs cannot be ascribed to a single toxic intermediate. In Caco-2 cells furazolid one is extensively metabolized and detoxified by GSH, in V79 is only partially activated and then bound to proteins.

ExcerptReferenceRelevance
" Three established cell lines were used to study the toxic effect of furazolidone (FZ), a widely used veterinary drug: HEp-2 cells, derived from a human larynx carcinoma, previously used in toxicity screening of several compounds; Caco-2 cells, derived from a human colon adenocarcinoma, able to differentiate partially in culture, and V 79, a fibroblast cell line derived from Chinese hamster lung, widely used to assess direct toxicants."( Established cell lines for safety assessment of food contaminants: differing furazolidone toxicity to V 79, HEp-2 and Caco-2 cells.
De Angelis, I; Hoogenboom, LA; Huveneers-Oorsprong, MB; Stammati, A; Zucco, F, 1994
)
0.75
" The cytotoxicity of nitrofuran drugs, therefore, cannot be ascribed to a single toxic intermediate, but in Caco-2 cells furazolidone is extensively metabolized and detoxified by GSH, in V79 is only partially activated and then bound to proteins, whereas in HEp-2, once activated, may react with DNA."( Metabolism of furazolidone: alternative pathways and modes of toxicity in different cell lines.
De Angelis, I; Hoogenboom, LA; Pedersen, JZ; Polman, TH; Rossi, L; Stammati, A; Vignoli, AL; Vincentini, O; Zucco, F, 1999
)
0.87
" pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects."( Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013
)
0.39
" The rate of adverse effects at 7 days with the active probiotic was 59."( Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013
)
0.39
"The use of this probiotic compound compared to placebo in the proposed regimen in Brazilian patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy or adverse effects."( Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013
)
0.39
"To evaluate the efficacy, compliance and adverse effects of 14-day amoxicillin and furazolidone-based quadruple regimen as rescue treatment for Helicobacter pylori (H."( [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Cheng, H; Dong, X; Gao, W; Hu, F; Liu, X, 2014
)
0.88
" Adverse effects were recorded at the end of treatment."( [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Cheng, H; Dong, X; Gao, W; Hu, F; Liu, X, 2014
)
0.66
" Mild and moderate adverse effects such as dizziness, nausea and diarrhea occurred in 43 patients (18."( [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Cheng, H; Dong, X; Gao, W; Hu, F; Liu, X, 2014
)
0.66
" The patients should be watched closely during the treatment since the adverse effects of this regimen happen frequently."( [Efficacy and safety of 14-day amoxicillin and furazolidone-based quadruple rescue regimen for eradication of Helicobacter pylori: a retrospective study].
Cheng, H; Dong, X; Gao, W; Hu, F; Liu, X, 2014
)
0.66
" Main outcome measures were the eradication rate and adverse reactions during medication."( Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice.
Ding, L; Lu, N; Qian, X; Shu, X; Song, C; Song, Y; Wang, H; Xie, Y; Xiong, Z; Ye, J; Yu, T; Zhu, Y, 2019
)
0.81
"Furazolidone-containing quadruple regimens proved both safe and highly effective in a real-world setting."( Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice.
Ding, L; Lu, N; Qian, X; Shu, X; Song, C; Song, Y; Wang, H; Xie, Y; Xiong, Z; Ye, J; Yu, T; Zhu, Y, 2019
)
2.25
" Primary outcomes were the risk of total adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) with 95% CI."( Safety of furazolidone-containing regimen in
Guo, CG; Ji, CR; Li, YY; Liu, J; Qu, JY; Zhang, Y; Zuo, X, 2020
)
0.96
" Adverse events were recorded during follow-up by telephone interview."( Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Cao, Y; He, W; Li, X; Wang, J, 2021
)
0.85
" The secondary endpoints were adverse effects, symptom improvement rates, and patient compliance."( Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X, 2022
)
0.72
" The incidence of adverse events in the HDDT group was significantly lower than that in the TFEB group (11."( Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X, 2022
)
0.72
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" Furazolidone decreases clearance of ethanol, increases its half-life with a simultaneous reduction of blood acetaldehyde concentration."( [Effect of drugs possessing antialcoholic activity on ethanol pharmacokinetics].
Deniskovets, AA; Lelevich, VV; Liopo, AV; Pron'ko, PS,
)
1.04
" The results showed that the concentration-time curves of furanodiene in rats after intravenous injection were fitted to a two-compartment model and the linear pharmacokinetic characteristic."( Pharmacokinetics and tissue distribution of furanodiene W/O/W multiple emulsions in rats by a fast and sensitive HPLC-APCI-MS/MS method.
Li, QS; Lin, WH; Lu, TT; Zhang, LF; Zhang, SQ, 2013
)
0.39

Compound-Compound Interactions

One week of furazolidone in combination with 2 weeks of amoxicillin, omeprazole, and bismuth subcitrate is a safe and cost-effective regimen for the eradication of H pylori.

ExcerptReferenceRelevance
" Four feeding trials were conducted to determine the performance of turkey poults when these compounds were used singly or in combination with 100 ppm of furazolidone."( Effect of including lasalocid or monensin singly or in combination with furazolidone on the growth and feed consumption of turkey poults.
Czarnecki, CM, 1990
)
0.71
"To study the efficacy and side effects of furazolidone when given for 1 week in combination with bismuth subcitrate, amoxicillin, and omeprazole."( Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.
Hasan, SR; Reza, PM; Roham, SR; Vahid, V,
)
0.75
"One week of furazolidone in combination with 2 weeks of amoxicillin, omeprazole, and bismuth subcitrate is a safe and cost-effective regimen for the eradication of H pylori."( Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.
Hasan, SR; Reza, PM; Roham, SR; Vahid, V,
)
0.86
"To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017."( Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication.
Chen, J; Chen, Q; Fang, HM; Huang, YT; Kan, LD; Li, LC; Qiu, Y; Yu, XL, 2020
)
0.73

Bioavailability

The oral bioavailability of parent furazolidone administered in solution was 58%, compared with 28% in a feed mixture. This gave rise to the misconception that furzolidone is poorly absorbed and inactivated in the intestine.

ExcerptReferenceRelevance
" Thus, the low systemic bioavailability is due to the considerable intestinal metabolism rather than a limited absorption."( [In vitro studies of intestinal absorption and biotransformation of furazolidone].
Klee, S; Ungemach, FR, 1992
)
0.52
" This gave rise to the misconception that furazolidone is poorly absorbed and inactivated in the intestine."( Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature.
White, AH, 1989
)
0.79
" The criteria on which such regulations are based include biological and chemical degradability, bioavailability (accumulation) and toxicity, the latter manifesting itself in a reduced ability of organisms to survive and reproduce."( The role of mutagenicity testing in the ecotoxicological evaluation of industrial discharges into the aquatic environment.
de Kreuk, JF; de Raat, WK; Hanstveit, AO, 1985
)
0.27
" The oral bioavailability of parent furazolidone administered in solution was 58%, compared with 28% in a feed mixture."( Furazolidone disposition after intravascular and oral dosing in the channel catfish.
el Said, KR; Plakas, SM; Stehly, GR, 1994
)
2.01
" Thus, the covalent binding of xenobiotics to macromolecular tissue constituents cannot necessarily be regarded as an irreversible endpoint of residue bioavailability and toxicity."( A contribution to safety assessment of veterinary drug residues: in vitro/ex vivo studies on the intestinal toxicity and transport of covalently bound residues.
Baumung, I; De Angelis, I; Horne, E; Klee, S; Kluge, K; O'Keeffe, M; Stammati, A; Ungemach, FR; Vignoli, AL; Zucco, F, 1999
)
0.3
" Short-term treatment with omeprazole did alter the relative bioavailability of this drug, probably through an effect on absorption kinetics or first-pass metabolism."( Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.
Calafatti, SA; Deguer, M; Martinez, M; Ortiz, RA; Pedrazzoli, J, 2001
)
0.53
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

modified tetracycline dosing demonstrated high efficacy. Thiamin, given at a dosage above the requirement of the vitamin for chickens, did not reduce anorexia or the TPP effect of furazolidone-treated birds.

ExcerptRelevanceReference
" The ulcer healing rate is related to the dosage and course of treatment."( Treatment of peptic ulcer disease with furazolidone.
Wang, YB; Zheng, ZT,
)
0.4
" It was concluded that standard recommendations for the therapeutic dosage of poultry with furazolidone may not be appropriate for breeding Japanese quail."( Production, hatchability and fertility of eggs from breeding Japanese quail (Coturnix coturnix japonica) fed diets containing furazolidone.
Arzey, GG; Dixon, RJ; Nicholls, PJ, 1992
)
0.71
" In order to determine this response, a dose-response relation of these cells to furazolidone and the kinetics of inactivation of the drug were studied."( An adaptive response of Vibrio cholerae strain OGAWA 154 to furazolidone.
Bhattacharya, R,
)
0.6
" After dosing adult swine orally with furazolidone (690 mg/animal per day) for 10 days no furazolidone was detected in liver, kidney and muscle (less than 2 ng/g)."( The elimination of furazolidone and its open-chain cyano-derivative from adult swine.
Berghmans, MC; Hekman, P; Hoogenboom, LA; Kuiper, HA; Vroomen, LH, 1987
)
0.87
" Then we dosed rats orally with these antibiotics and isolated the intensely yellow, polar metabolites from their urine."( Oxidative metabolites of 5-nitrofurans.
Hoener, BA; Krueger, TR; Streeter, AJ, 1988
)
0.27
"A controlled comparison of furazolidone and tetracycline in the treatment of cholera indicates that, in either dosage used, furazolidone reduced total stool volume by 50% and duration of diarrhoea by 40%."( Controlled comparison of tetracycline and furazolidone in cholera.
Banwell, JG; Caranasos, GJ; Keimowitz, RI; Mitra, RC; Mondal, A; Pierce, NF; Thomas, J, 1968
)
0.81
" The trials suffered from unclear methods, variability in study populations and total dosage of medication used, inaccuracy in determining outcomes, and inadequate sample sizes."( Issues in clinical parasitology: the treatment of giardiasis.
Davidson, RA, 1984
)
0.27
"Newly hatched male White Pekin ducklings were fed furazolidone (FZ) at dosage of 750 mg/kg of feed for 4 weeks."( Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations.
Ferrans, VJ; Van Vleet, JF, 1983
)
1.96
" Thiamin, given at a dosage above the requirement of the vitamin for chickens, did not reduce the anorexia or the TPP effect of furazolidone-treated birds, although it stimulated the feed intake and growth of birds on unmedicated feed."( Anorexia and antagonism of thiamin utilization in poultry treated with furazolidone.
Ali, BH; Bartlet, AL, 1982
)
0.7
" Tinidazole is a very promising drug, being effective in single dosage with infrequent side effects."( The treatment of giardiasis.
Mendelson, RM, 1980
)
0.26
" [14C]Furazolidone was administered by intravascular or oral routes in a single dosage of 1 mg/kg body weight."( Furazolidone disposition after intravascular and oral dosing in the channel catfish.
el Said, KR; Plakas, SM; Stehly, GR, 1994
)
2.21
" Incurred NFZ levels exceeded 400 ng drug/g tissue at 2 h after dosing but decreased rapidly to approximately 1 ng drug/g tissue by 8 h after dosing, as determined by this method."( Simultaneous determination of nitrofurazone, nitrofurantoin, and furazolidone in channel catfish (Ictalurus punctatus) muscle tissue by liquid chromatography.
Long, AR; Munns, RK; Plakas, SM; Rupp, HS,
)
0.37
" The formation of protein-bound 14C in the liver was investigated further with trout dosed intravenously with different 14C-FZ doses at 10 degrees C or with 5 mg/kg FZ at different water temperatures."( Binding of 14C-furazolidone metabolites to the muscular and hepatic proteins of trout.
Law, FC; Meng, J,
)
0.48
"The bivariate calibration algorithm was applied to the spectrophotometric determination of metronidazole, furazolidone and di-iodohydroxyquinoline in pharmaceutical dosage forms."( Application of the bivariate spectrophotometric method for the determination of metronidazole, furazolidone and di-iodohydroxyquinoline in pharmaceutical formulations.
Amador-Hernández, J; López-de-Alba, PL; López-Martínez, L; Wróbel, K; Yepez-Murrieta, ML, 1997
)
0.73
" The patient should be instructed to insert two vaginal suppositories daily for the first week, then to decrease the dosage gradually as indicated by the physician after clinical examination and microscopic examination of vaginal secretions each week."( Trichomonal vaginitis; the problem of chronic or recurring infection.
KERNER, JA; MARGOLIS, AJ, 1958
)
0.24
" 36 adult pigeons were treated with 2 different oral modes of application (capsule/drinking water) with a daily therapeutic dosage of 12."( [The efficacy of different oral dosage forms of furazolidone for E. coli infections in carrier pigeons].
Krautwald-Junghanns, ME; Reitz, N; Richter, A; Schmidt, V,
)
0.39
"To study the dose-response relation of the fish drugs and their joint toxicity on the luminescent bacteria."( [A study on toxicity of aquaculture drugs to luminescent bacteria].
Liu, H; Ma, J; Shi, C; Wu, S, 2008
)
0.35
" Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes."( Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008
)
0.35
" Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration."( A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Bari, Z; Fakheri, H; Sardarian, H, 2012
)
0.61
"We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients."( Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Bao, ZJ; Huang, YQ; Shi, DM; Xiang, P; Xiao, L; Yin, SM; Zhang, F; Zhang, GS, 2016
)
0.43
"In a real-world experience, modified tetracycline dosing as part of tetracycline and furazolidone quadruple therapy for 14 d demonstrated high efficacy, comparable to standard tetracycline dose regimens, with a favorable safety profile."( Efficacy and safety of modified tetracycline dosing in a quadruple therapy for
Chen, XQ; Du, Q; Hu, WL; Kim, JJ; Sun, YC; Wang, XJ; Yue, L; Zhao, YR; Zhu, MJ, 2023
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
EC 1.4.3.4 (monoamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
antitrichomonal drugA drug used to treat trichomonas infections.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxazolidines
nitrofuran antibioticA member of the class of furans in which the furan ring is substituted by a nitro group and which also has significant antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency100.00005.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency11.22020.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency25.11890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.17930.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency64.77570.031637.5844354.8130AID504865; AID743255
TDP1 proteinHomo sapiens (human)Potency16.66360.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency18.47770.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.98260.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.17720.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency6.86040.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.67460.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.12470.000229.305416,493.5996AID1259248; AID743075; AID743077; AID743079; AID743080
cytochrome P450 2D6Homo sapiens (human)Potency10.91200.00108.379861.1304AID1645840
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.63100.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.53540.023723.228263.5986AID743223
alpha-galactosidaseHomo sapiens (human)Potency39.81074.466818.391635.4813AID1467
aryl hydrocarbon receptorHomo sapiens (human)Potency26.60320.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency0.55200.039147.5451146.8240AID1224845
serine-protein kinase ATM isoform aHomo sapiens (human)Potency22.38720.707925.111941.2351AID485349
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.00000.316212.443531.6228AID902; AID924
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency89.12515.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency89.12515.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency15.87160.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency3.16230.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.50120.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency10.32250.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency5.62340.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency4.46680.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
twin arginine protein translocation system - TatA proteinEscherichia coli str. K-12 substr. MG1655AC5017.81200.707010.915145.8560AID504941
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID285162Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID689774Selectivity index, ratio of CC50 for Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv isolate SRI2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID285161Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID689772Antitubercular activity against Mycobacterium tuberculosis H37Rv incubated for 10 days in anaerobic condition followed by 48 hrs incubation in aerobic condition by LORA assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1323835Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1323834Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID285159Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID285160Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID689770Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate SRI after 5 days by resazurin-based microplate assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID689771Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate ITR after 7 days by luminescence spectrometry2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID689773Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,198)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990765 (63.86)18.7374
1990's151 (12.60)18.2507
2000's118 (9.85)29.6817
2010's102 (8.51)24.3611
2020's62 (5.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.71 (24.57)
Research Supply Index7.27 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index135.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials132 (10.08%)5.53%
Trials0 (0.00%)5.53%
Reviews63 (4.81%)6.00%
Reviews2 (6.67%)6.00%
Case Studies33 (2.52%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.08%)0.25%
Observational0 (0.00%)0.25%
Other1,081 (82.52%)84.16%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy [NCT04678492]Phase 4658 participants (Actual)Interventional2020-12-20Completed
Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy [NCT03609892]Phase 4658 participants (Actual)Interventional2018-08-01Completed
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial [NCT03658746]Phase 4420 participants (Actual)Interventional2019-01-01Completed
10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail [NCT03571230]Phase 4400 participants (Anticipated)Interventional2018-07-01Not yet recruiting
Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study [NCT03658733]Phase 4120 participants (Anticipated)Interventional2018-12-15Not yet recruiting
Gastrointestinal Preparation and Efficacy of Saccharomyces Boulardii as a Pre-treatment for Helicobacter Pylori Rescue Therapy [NCT05191875]106 participants (Actual)Interventional2021-12-01Completed
Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: a Pilot Study [NCT03616405]Phase 460 participants (Anticipated)Interventional2019-04-01Not yet recruiting
Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study [NCT05135182]Phase 4170 participants (Anticipated)Interventional2021-11-28Recruiting
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori: A Pilot Study [NCT04991584]60 participants (Anticipated)Interventional2021-08-04Not yet recruiting
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication [NCT03716622]Phase 4350 participants (Actual)Interventional2018-07-31Completed
The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study [NCT03342456]Phase 4184 participants (Actual)Interventional2017-12-13Completed
Construction and Application of the Treatment of Refractory Helicobacter Pylori Infection Based on the High-throughput Sequencing Technologies [NCT02741414]4,428 participants (Anticipated)Interventional2016-06-30Recruiting
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori: A Pilot Study [NCT03726099]Phase 460 participants (Anticipated)Interventional2019-03-15Recruiting
The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure [NCT05173493]670 participants (Actual)Observational2021-12-30Completed
Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy [NCT06168084]Phase 4688 participants (Anticipated)Interventional2023-06-06Recruiting
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study [NCT05126121]60 participants (Anticipated)Interventional2021-11-20Not yet recruiting
Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy [NCT02894268]Phase 4300 participants (Anticipated)Interventional2016-02-29Recruiting
A Study on the Efficacy and Safety of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection [NCT05410223]100 participants (Anticipated)Interventional2021-04-06Recruiting
Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial [NCT05549115]500 participants (Anticipated)Interventional2022-09-20Recruiting
Quadruple Therapy Using Esomeprazole, Colloidal Bismuth Subcitrate, Amoxicillin-Clavulanate, and Furazolidone in Patients Who Failed to Eradicate H. Pylori With Triple Therapy [NCT00520949]176 participants (Actual)Interventional2006-10-31Completed
Comparison of Vonoprazan Fumarate-based Triple Therapy Versus Proton Pump Inhibitor and Bismuth Based Quadruple Therapy in the Eradication of Helicobacter Pylori: a Single-center Prospective Open-label Controlled Study [NCT05097846]100 participants (Anticipated)Interventional2021-06-17Recruiting
Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection [NCT05718609]Phase 4855 participants (Anticipated)Interventional2023-03-01Recruiting
Helicobacter Pylori Treatment [NCT01668927]Phase 4424 participants (Actual)Interventional2012-07-31Completed
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure [NCT04810793]820 participants (Actual)Observational [Patient Registry]2020-07-01Completed
Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication: A Single-center, Randomised, Controlled Trial. [NCT06168214]Phase 41,404 participants (Anticipated)Interventional2023-09-04Recruiting
Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment [NCT02988089]Phase 4480 participants (Anticipated)Interventional2017-04-20Recruiting
Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study [NCT04264663]Phase 4250 participants (Anticipated)Interventional2019-11-01Recruiting
Efficacy and Safety of Helicobacter Pylori Eradication Dual or Triple Regimes Using Vonoprazan as the Antacid [NCT05345210]Phase 4500 participants (Anticipated)Interventional2022-04-25Recruiting
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment [NCT03139253]Phase 4120 participants (Anticipated)Interventional2017-05-30Not yet recruiting
Efficacy and Safety of Furazolidone-based Quadruple Therapy With Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication: A Prospective Randomized Trial [NCT04907747]Phase 4234 participants (Anticipated)Interventional2021-05-18Recruiting
Eradication Efficacy and Safety of High-dose Dual Therapy Compared With Furazolidone-based Quadruple Therapy as a Rescue Treatment for Helicobacter Pylori Infection: a Randomized Controlled Trial [NCT05176821]186 participants (Anticipated)Interventional2021-01-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]